Strategic Medicine, BV (The Hague, The Netherlands) and Strategic Medicine, Inc. (PA, USA) deliver products and services to therapeutic and diagnostic companies, healthcare providers and payers and the investment community based on unique methodologies for modeling disease processes, from predisease through diagnosis, disease and patient stratification and outcome. Strategic Medicine, Inc. focuses on the development of disease models that design and incorporate a personalized health record to model the progression of a patient from genetic risk, through interaction with lifestyle and environment, to early disease detection, disease and patient stratification and treatment decision support for enhanced outcomes. This model involves the integration of disparate data and databases, evaluation of data quality and completeness, data simulation (when necessary), systems modeling and quantitative risk/opportunity evaluation. Strategic Medicine, Inc. has been involved in applying these approaches in oncology, cardiology, women's health and pediatric conditions and rare diseases, and has focused on the development of both disease- and data-agnostic infrastructures and analytics.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pme.13.62 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Maximizing the safety and sustainability of MXenes.
Sci Rep
December 2024
Environmental Systems Analysis, Chalmers University of Technology, Gothenburg, 412 96, Sweden.
Safe and Sustainable by Design (SSbD) is a new regulatory concept guiding chemical and material innovation. The European Commission has recommended a two-stage SSbD framework and plan to revise it based on stakeholder feedback. The framework involves establishing key (re)design SSbD principles and assessment of the final innovation, however the applicability of the framework to advanced materials remains to be addressed.
View Article and Find Full Text PDFN-acetylation of α-synuclein enhances synaptic vesicle clustering mediated by α-synuclein and lysophosphatidylcholine.
Elife
December 2024
Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
Previously, we reported that α-synuclein (α-syn) clusters synaptic vesicles (SV) Diao et al., 2013, and neutral phospholipid lysophosphatidylcholine (LPC) can mediate this clustering Lai et al., 2023.
View Article and Find Full Text PDFEpidemiology and Molecular Characterisation of Multidrug-Resistant Isolated from Cow Milk.
Vet Sci
November 2024
Faculty of Veterinary Medicine, Chattogram Veterinary and Animal Sciences University, Chattogram 4225, Bangladesh.
Antimicrobial resistance (AMR) is a growing global concern and poses a significant threat to public health. The emergence of multidrug-resistant organisms, including , also presents a risk of transmission to humans through the food chain, including milk. This study aimed to investigate the prevalence of in raw milk in the Chattogram metropolitan area (CMA) of Bangladesh and their phenotypic and genotypic antimicrobial resistance patterns.
View Article and Find Full Text PDFSex differences in clinically diagnosed psychiatric disorders over the lifespan: a nationwide register-based study in Sweden.
Lancet Reg Health Eur
December 2024
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Background: Limited studies exist on sex differences in incidence rates of psychiatric disorders across the lifespan. This study aims to analyze sex differences in the incidence rates of clinically diagnosed psychiatric disorders over the lifespan.
Methods: We conducted a nationwide register-based cohort study, including all individuals who were born in Sweden and lived in Sweden between 2003 and 2019, including 4,818,071 females and 4,837,829 males.
Preventative treatment of tuberous sclerosis complex with sirolimus: Phase I safety and efficacy results.
Ann Child Neurol Soc
June 2024
Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Objective: Tuberous sclerosis complex (TSC) results from overactivity of the mechanistic target of rapamycin (mTOR). Sirolimus and everolimus are mTOR inhibitors that treat most facets of TSC but are understudied in infants. We sought to understand the safety and potential efficacy of preventative sirolimus in infants with TSC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!